Hively Brad 的 Form 4/A 修正申報
修正Starling Oncology, Inc.（DFPH），2025/4/28 申報
- 申報編號
- 0000935836-25-000296
- 申報時間
- 2025/4/28 19:20 ET
- 交易日
- 2025/3/26
- 申報延遲
- 33 天
- 10b5-1 計畫
- 沒有勾選
- 原始申報日
- 2025/3/28
這份申報列了 1 筆非衍生性交易、1 筆衍生性交易。公開市場買進合計 $4.72 萬。交易後 33 天申報。
這份修正申報取代了 0001079973-25-000521（2025/3/28 申報）。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Hively BradCIK 0001891124 | 董事 |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2025/3/26 | Common Stock | P買進取得 | +45,280 | $1.04F4 | +$47,168.18 | 712,033 | 直接 |
衍生性證券（表 II）
選擇權、認股權證、限制型股票單位等。股數是標的股票的股數；單價與金額是衍生證券本身的價格，交易後持有是衍生證券的單位數。
| 交易日 | 證券 | 交易 | 標的股數 | 單價 | 金額 | 交易後持有 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2025/3/26 | Common Stock | P買進取得 | +22,640 | $0.125F4 | +$2,830 | 22,640 | 直接 |
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
This amendment is filed to correct the number of shares of Common Stock and number of Common Warrants acquired by the reporting person in the transaction reported on the original Form 4 filed on March 28, 2025. As a result of this correction, the amount of securities beneficially owned following the reported transaction specified in Table I, Column 5 and Table II, Column 9 have also been corrected.
- F2
Represents securities purchased in a private placement transaction directly from the Company pursuant to a Securities Purchase Agreement, dated March 24, 2025 (the "Private Placement"). Pursuant to the terms of the Securities Purchase Agreement, the Company issued the reporting person Private Placement units consisting of two shares of the Company's common stock ("Common Stock") and a common warrant ("Common Warrant") to purchase one share of Common Stock (the "Private Placement Unit").
- F3
The issuance of the securities to the reporting person pursuant to the Private Placement was approved by the Company's board of directors and was deemed an exempt transaction pursuant to Rule 16b-3 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").
- F4
Each Private Placement Unit was purchased at a price of $2.2084 per unit, with a cost per share of Common Stock of $1.0417 and a cost per Common Warrant of $0.1250.
表 I 有 1 筆、表 II 有 1 筆交易的價格引用這則附註。
- F5
The reporting person may not exercise any portion of a Common Warrant to the extent that the reporting person would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately prior to or after giving effect to such exercise, as such percentage ownership is determined in accordance with Section 13(d) under the Exchange Act.